Verona Pharma Statistics
Share Statistics
Verona Pharma has 81.83M shares outstanding. The number of shares has increased by 1.43% in one year.
| Shares Outstanding | 81.83M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 68.91M |
| Failed to Deliver (FTD) Shares | 27.43K |
| FTD / Avg. Volume | 2.78% |
Short Selling Information
The latest short interest is 7.52M, so 9.19% of the outstanding shares have been sold short.
| Short Interest | 7.52M |
| Short % of Shares Out | 9.19% |
| Short % of Float | 10.93% |
| Short Ratio (days to cover) | 8.04 |
Valuation Ratios
The PE ratio is -28.98 and the forward PE ratio is -138.36.
| PE Ratio | -28.98 |
| Forward PE | -138.36 |
| PS Ratio | 0 |
| Forward PS | 42.4 |
| PB Ratio | 6.32 |
| P/FCF Ratio | -31.38 |
| PEG Ratio | n/a |
Enterprise Valuation
Verona Pharma has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 33.33, with a Debt / Equity ratio of 0.19.
| Current Ratio | 33.33 |
| Quick Ratio | 33.33 |
| Debt / Equity | 0.19 |
| Total Debt / Capitalization | 16.25 |
| Cash Flow / Debt | -1.04 |
| Interest Coverage | -32.85 |
Financial Efficiency
Return on equity (ROE) is -0.22% and return on capital (ROIC) is -22.31%.
| Return on Equity (ROE) | -0.22% |
| Return on Assets (ROA) | -0.18% |
| Return on Capital (ROIC) | -22.31% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -688.22K |
| Employee Count | 79 |
| Asset Turnover | 0 |
| Inventory Turnover | 679.62K |
Taxes
| Income Tax | -632.44K |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by 139.78% in the last 52 weeks. The beta is 0.42, so Verona Pharma's price volatility has been higher than the market average.
| Beta | 0.42 |
| 52-Week Price Change | 139.78% |
| 50-Day Moving Average | 36.39 |
| 200-Day Moving Average | 23.57 |
| Relative Strength Index (RSI) | 55.26 |
| Average Volume (20 Days) | 988.57K |
Income Statement
In the last 12 months, Verona Pharma had revenue of $0 and earned -$54.37M in profits. Earnings per share was $-0.54.
| Revenue | 0 |
| Gross Profit | -679.62K |
| Operating Income | -67.83M |
| Net Income | -54.37M |
| EBITDA | -52.47M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.54 |
Balance Sheet
The company has $271.77M in cash and $51.33M in debt, giving a net cash position of $220.44M.
| Cash & Cash Equivalents | 271.77M |
| Total Debt | 51.33M |
| Net Cash | 220.44M |
| Retained Earnings | -388.43M |
| Total Assets | 381.82M |
| Working Capital | 336.30M |
Cash Flow
In the last 12 months, operating cash flow was -$50.22M and capital expenditures $0, giving a free cash flow of -$50.22M.
| Operating Cash Flow | -50.22M |
| Capital Expenditures | 0 |
| Free Cash Flow | -50.22M |
| FCF Per Share | -0.63 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
VRNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.3% |
| FCF Yield | -1.48% |
Analyst Forecast
The average price target for VRNA is $42, which is 1.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $42 |
| Price Target Difference | 1.4% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 5.85 |
| Piotroski F-Score | 3 |